EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study

Eva Herweijer, Kaisa Miikkulainen, Oskar Eklund, Brett Doble, Christoffer Holmberg, Viktor Hedlöf Kanje, Robyn Thorén, Christina Victoria Jones, Magnus Björkholm

The European Journal of Health Economics · 13.07.2026

DOI: 10.1007/s10198-026-01964-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift The European Journal of Health Economics, online erschienen am 13.07.2026. Verfasst von Eva Herweijer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ciencia Research AB, Drottninggatan 33, 111 51, Stockholm, Sweden. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences AB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To describe healthcare resource utilization (HCRU), direct costs, and survival of DLBCL patients in Sweden.

Methods

This retrospective cohort study followed adult patients with DLBCL from 2015 to 2023 using Swedish national registers. Time in specialty care was calculated as days per-person-year (PPY). Nordic diagnosis-related-group weights were used to estimate costs.

Results

7,503 patients were diagnosed with DLBCL. Median age was 73.0 years; 56.9% male and 55.0% had ≥ 1 comorbidity. On average, patients spent 17.6 days (4.8% annually) PPY in care, with average costs of €15,417 PPY. HCRU was highest in the first and second year with 41.7 days (11.4%) and 12.6 days (3.5%) in care, respectively. Average time in care declined from 13.7 days (3.8%) in 2015 to 11.9 days (3.3%) in 2019, then stabilized. Overall survival was 76.5% (95%CI: 75.5–77.4) and 68.9% (95%CI: 67.9–70.0) at 1 and 2 years from diagnosis.

Conclusions

DLBCL patients spent considerable time in specialist care, especially in the first two years post-diagnosis. Care use and costs remained stable over the period. This study provides the first population-level estimates of HCRU and direct costs for DLBCL in Sweden, offering valuable context for current management and future integration of evolving treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

CAR T-cell therapyDiffuse large B-cell lymphomaDirect costsHealthcare resource utilizationReal-world dataSpecialist care

Autor:innen und Institutionen

  • Ciencia Research AB, Drottninggatan 33, 111 51, Stockholm, Sweden.
  • Gilead Sciences Sweden AB, Solna, Stockholm, Sweden.
  • Kite, a Gilead Company, Santa Monica, USA.
  • Ciencia Research AB, Drottninggatan 33, 111 51, Stockholm, Sweden. robyn.thoren@cienciaresearch.com.
  • Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.
  • Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Förderung

  • Gilead Sciences AB

Zitieren

APA

Herweijer, E., Miikkulainen, K., Eklund, O., Doble, B., Holmberg, C., Kanje, V. H., Thorén, R., Jones, C. V., & Björkholm, M. (2026). Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study. The European Journal of Health Economics. https://doi.org/10.1007/s10198-026-01964-x

Vancouver

Herweijer E, Miikkulainen K, Eklund O, Doble B, Holmberg C, Kanje VH, et al. Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study. The European Journal of Health Economics. 2026. doi:10.1007/s10198-026-01964-x

BibTeX
@article{Herweijer2026,
  author = {Herweijer, Eva and Miikkulainen, Kaisa and Eklund, Oskar and Doble, Brett and Holmberg, Christoffer and Kanje, Viktor Hedlöf and Thorén, Robyn and Jones, Christina Victoria and Björkholm, Magnus},
  title = {Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study},
  journal = {The European Journal of Health Economics},
  year = {2026},
  doi = {10.1007/s10198-026-01964-x}
}
Kostenlos starten →